BeSt, BehandelStrategieën in Reumatoïde Artritis.

Completed

• Registration Number: NL-OMON24149
• Lead Sponsor: Dutch College of Health Insurance Companies

Brief Summary

1. Arthritis Rheum. 2005 Nov;52(11):3381-90. <br> 2. Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-77-82. <br> 3. Ann Intern Med. 2007 Mar 20;146(6):406-15. <br> 4. Ann Rheum Dis. 2007 Sep;66(9):1227-32. Epub 2007 Apr 3. <br> 5. J Rheumatol Suppl. 2007 Nov;80:25-33. <br> 6. Arthritis Rheum. 2008 Feb;58(2 Suppl):S126-35. <br> 7. Arthritis Rheum. 2008 May;58(5):1293-8.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 508

Inclusion Criteria

Patients (18 years or older) with rheumatoid arthritis (ACR 1987 criteria), diagnosis since less than 2 years, previously untreated with DMARDs, with active disease (at least 6/66 swollen and at least 6/68 painfull joints, and either ESR 28 mm or more or VAS general wellbeing (by patient) of 20 mm or more).

Exclusion Criteria

1. Previous therapy with DMARDs except for hydroxychloroquine;

2. Pregnancy or wish to become pregnant during the study, or childbearing potential without adequate contraception;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
After 2 years of follow-up: functional ability as measured by HAQ (collected by blinded research nurse) and joint damage on X-rays of hands and feet (Sharp/van der Heijde method, random in time, by 2 independent physicians, X-rays masked for center and patient identity).

Secondary Outcome Measures

Name	Time	Method
1. Side effects;<br /><br>2. Quality of life;<br /><br>3. Utilities; <br /><br>4. Costs.